Bexar County Commissioners Court gave preliminary approval to award $10 million to UT Health San Antonio and The University of Texas at San Antonio for development of The University of Texas School of Public Health San Antonio. Among the shared goals of the collaboration are to improve health outcomes of the local population and meet a growing demand for public health education.
Today’s issue of San Antonio Business Journal includes a special section detailing the broad scope of cancer patient care and lifesaving research at Mays Cancer Center at UT Health San Antonio. The conversation features center experts discussing the benefits of having a National Cancer Institute-Designated Cancer Center in the city’s backyard. You can also read a summary and watch the webinar recording.
The School of Nursing has received $16 million from the Texas Department of Health and Human Services to expand its successful Casa Mia recovery program for pregnant and parenting mothers with opioid use disorder and their children.
The compound ERX-41, developed by UT Health San Antonio scientists, exploits a previously unrecognized weakness in breast cancer and other tumors. The findings could lead to new drugs to fight a range of cancers.
Dr. Ronald Stewart, chairman of the Department of Surgery, treated victims of the Uvalde school shootings and discussed the national crisis of firearm violence at an American College of Surgeons briefing in Washington.
Dr. Dodge oversaw completion of UT Health San Antonio’s state-of-the-art Center for Oral Health Care & Research. He served the university for 40 years, including as dean of the dental school from 2013 until his retirement in 2018.
How do we turn discoveries into lifesaving health care? From fighting disease to making research breakthroughs, we do everything it takes to lead the way to develop new therapies and treatments to care for you. See how we’re changing lives and find a provider.
James D. Lechleiter, PhD, professor of cell systems and anatomy at UT Health San Antonio, and Andrea Giuffrida, PhD, vice president for strategic industry ventures at UT Health San Antonio, were quoted in this story about the first human test of experimental brain injury medication conceived in laboratories at UT Health San Antonio.